Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down – Time to Sell?

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY) gapped down before the market opened on Monday . The stock had previously closed at $18.84, but opened at $18.07. Daiichi Sankyo shares last traded at $18.20, with a volume of 1,913 shares.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Jefferies Financial Group lowered shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a report on Thursday, July 30th. Zacks Research cut shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Daiichi Sankyo presently has a consensus rating of “Reduce”.

Daiichi Sankyo Price Performance

The company has a market capitalization of $34.99 billion, a PE ratio of 21.84, a price-to-earnings-growth ratio of 2.59 and a beta of -0.11. The company has a debt-to-equity ratio of 0.29, a current ratio of 2.92 and a quick ratio of 1.96. The stock’s 50 day simple moving average is $17.58 and its 200-day simple moving average is $17.25.

Daiichi Sankyo (OTCMKTS:DSNKY) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.35%. The business had revenue of $3.61 billion during the quarter, compared to analysts’ expectations of $3.32 billion. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, equities analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.97 earnings per share for the current fiscal year.

Daiichi Sankyo Company Profile

Daiichi Sankyo Co, Ltd. is a Japan-based pharmaceutical company focused on the research, development, manufacture and commercialization of medicines. Its primary areas of activity include oncology, cardiovascular disease, and other specialty therapeutic fields, with an emphasis on innovative treatments and technologies.

The company is particularly known for its antibody-drug conjugate (ADC) platform, which is designed to deliver potent cancer medicines directly to tumor cells. Daiichi Sankyo’s oncology portfolio includes Enhertu (trastuzumab deruxtecan), developed in collaboration with AstraZeneca, as well as other marketed and investigational ADC therapies.